Background: Diosmin has already been described and documented to be neuroprotective, antioxidant and anti-inflammatory. It may possess or hold depressionalleviating activity. Therefore, the purpose of the current research protocol is to investigate the depression-relieving proficiency of diosmin in stressed and unstressed mice. Methods: Male mice (Swiss albino) were imperiled to an unpredictable chronic stress paradigm every day for three sequential weeks, and depression-resembling behavioral despair was induced. Imipramine 15 mg/kg and diosmin (25, 50 and 100 mg/kg) were dispensed for 21 successive days to discrete groups of stressed and unstressed mice. Results: Both diosmin (100 mg/kg) and 15 mg/kg imipramine administration for 3 consecutive weeks substantially or significantly diminished the immobility period of mice imperiled to stress in comparison to stressed mice gauzed with the vehicle. Diosmin (25, 50 and 100 mg/kg) and imipramine considerably reinstated the diminished sucrose proclivity (sucrose preference percentage; %) in stressed mice, demonstrating their considerable or substantial depression-relieving effects. The locomotor activities of mice were not considerably altered by these drugs. Antidepressant-like activity of diosmin for immobility periods and preference for sucrose was observed to be analogous to imipramine. Diosmin (100 mg/kg) and imipramine substantially quashed CUMS- persuaded escalation of plasma corticosterone and nitrite levels, malondialdehyde levels and MAO-A activity in the brain of stressed mice. Both drugs also substantially reversed CUMS-prompted reduction in catalase activity and brain glutathione levels. Conclusion: Accordingly, diosmin revealed significant anti-depressive activity in mice imperiled to chronic mild unpredictable stress paradigm conceivably via mitigation of nitrosative and oxidative stress, reticence of brain MAO-A action, and sink drop of plasma corticosterone degrees.

Introduction: Cannabigerol (CBG), being one of the non-psychotropic phyto-cannabinoid, has been labelled and recognized to be antioxidant and neuroprotective; it may conceivably hold depression-relieving activity. Consequently, the objective of the present research procedure was to explore the depression-alleviating competence of cannabigerol in both stressed and unstressed mice using computational/in-silico modelling, followed by in-vivo analysis. Methods: Target genes for Major Depressive Disorder (MDD) were identified using GeneCards and Swiss Target Prediction, with common targets screened via Venny software. STRING database anal-ysis established protein-protein interactions (PPI), identifying CNR2 (CB2 receptor) as a key target. Molecular docking of CBG with CB2 (PDB ID: 8GUR) showed strong binding, prompting in vivo evaluation. ADME profiling via Schrödinger Maestro v10.5 confirmed CBG’s high oral absorption and favorable pharmacokinetics. Male Swiss albino mice underwent chronic unpredictable mild stress (CUMS) for three successive weeks, with CBG (10, 20, 40 mg/kg) and imipramine (15 mg/kg) administered and various behavioral and biochemical parameters being analyzed. Results: Cannabigerol demonstrated maximum oral absorption in ADME predictions using Schrö-dinger's Maestro (v10.5). Wayne diagram illustrated MDD-related targets, with CB2 (CNR2) rank-ings in top targets, based on SwissADME and Venny software analysis. Docking analysis revealed a high binding affinity (-10.53) for CB2, outperforming cannabidiol (-9.56) and comparable to Δ9-THC (-10.11). During in vivo evaluation, CBG (40 mg/kg) and Imipramine 15mg/kg significantly reduced CUMS-induced exalted plasma corticosterone, nitrite quantities, and monoamine oxidase-A action in the brain of stressed mice. Additionally, both treatments substantially reversed the unpre-dictable chronic stress-induced decline in catalase action, demonstrating CBG’s possible potential in alleviating depression-like symptoms in mice. Conclusion: Cannabigerol has shown significant depressive alleviating potential in mice exposed to chronic and unpredictable stress regimes, possibly via interaction with cannabinoid receptors as in-dicated by in-silico modelling, which has been validated by our findings of the in-vivo protocol.

Background: The triazole analogues are molecules of immense attraction because of their wide pharmacological applications. Methods: Present research deals with the synthesis of triazole-2-thione analogues and their QSAR study. The synthesized analogs are also evaluated for their antimicrobial, anti-inflammatory, and antioxidant effect. Results: It was revealed that the benzamide analogues (3a, 3d) and triazolidine analogue (4b) were found to be most active against P. aeruginosa and E. coli with pMIC values of 1.69, 1.69 and 1.72, respectively. The antioxidant study of the derivatives showed that 4b was the most active antioxidant with 79% protein denaturation inhibition. The highest anti-inflammatory activity was shown by 3f, 4a and 4f. Conclusion: This study provides certain potent leads for further development of more potential anti- inflammatory, antioxidant and antimicrobial agents

Background: Cannabidivarin, a non-psychotropic phytocannabinoid, has been identified and recognized for its antioxidant and neuroprotective properties, with potential effects on central nervous system (CNS) ailments. Objective: The purpose of the present study was to investigate the antidepressant potential of cannabidivarin in both stressed and unstressed mice via the CUMS (chronic unpredictable mild stress) model through in vivo analysis. Methods: Swiss male albino mice were exposed to the CUMS protocol daily for three consecutive weeks, resulting in depression-like behavioral symptoms. Imipramine at a dose of 15 mg/kg and cannabidivarin at doses of 50, 100, and 200 mg/kg were administered for three weeks to different groups of both stressed and unstressed mice. Results: Both imipramine (15 mg/kg) and cannabidivarin (200 mg/kg), after 21 consecutive days of administration, significantly reduced the immobility time in mice exposed to stress compared to the stressed group given saline. Neither treatment significantly affected the locomotor activity in either stressed or unstressed mice. Cannabidivarin showed antidepressant potential by reducing immobility in stressed mice, similar to imipramine, at a dose of 15 mg/kg. Additionally, both cannabidivarin (200 mg/kg) and imipramine (15 mg/kg) significantly lowered elevated plasma corticosterone, nitrite levels, and monoamine oxidase-A activity in the brains of stressed mice. Both treatments also notably reversed the chronic stress-induced decrease in catalase activity. Conclusion: In conclusion, cannabidivarin demonstrated significant antidepressant effects in mice exposed to chronic unpredictable stress using the CUMS model. These effects are likely mediated through its interaction with cannabinoid receptors, as supported by in vivo findings and the well-established role of endocannabinoid receptors in modulating responses to phytocannabinoids.